The Clostridium difficile cpr locus is regulated by a noncontiguous two-component system in response to type A and B lantibiotics.
about
Protein Defense Systems against the Lantibiotic Nisin: Function of the Immunity Protein NisI and the Resistance Protein NSRLantibiotic resistance.Functional genomics reveals that Clostridium difficile Spo0A coordinates sporulation, virulence and metabolismConserved oligopeptide permeases modulate sporulation initiation in Clostridium difficile.Initiation of sporulation in Clostridium difficile: a twist on the classic modelSynthetic polymers active against Clostridium difficile vegetative cell growth and spore outgrowthAntimicrobial Peptide Resistance Mechanisms of Gram-Positive Bacteria.An alkaline phosphatase reporter for use in Clostridium difficile.Effects of surotomycin on Clostridium difficile viability and toxin production in vitroStructure of the Response Regulator NsrR from Streptococcus agalactiae, Which Is Involved in Lantibiotic Resistance.Bacterial Evasion of Host Antimicrobial Peptide DefensesA novel regulator controls Clostridium difficile sporulation, motility and toxin productionThe Clostridium difficile Dlt Pathway Is Controlled by the Extracytoplasmic Function Sigma Factor σV in Response to Lysozyme.The second messenger cyclic Di-GMP regulates Clostridium difficile toxin production by controlling expression of sigDThe Phosphotransfer Protein CD1492 Represses Sporulation Initiation in Clostridium difficile.A tale of two machines: a review of the BLAST meeting, Tucson, AZ, 20-24 January 2013.Employing the promiscuity of lantibiotic biosynthetic machineries to produce novel antimicrobials.Regulation of antimicrobial resistance by extracytoplasmic function (ECF) sigma factors.Bacteriocin-Antimicrobial Synergy: A Medical and Food Perspective.Overexpression, purification and crystallization of the response regulator NsrR involved in nisin resistanceThe N-terminal Region of Nisin Is Important for the BceAB-Type ABC Transporter NsrFP from Streptococcus agalactiae COH1.Improving the attrition rate of Lanthipeptide discovery for commercial applications.Insight into Two ABC Transporter Families Involved in Lantibiotic Resistance.Mutacin 1140 Lantibiotic Variants Are Efficacious Against Clostridium difficile Infection.OG716: Designing a fit-for-purpose lantibiotic for the treatment of Clostridium difficile infections.The C. difficile clnRAB operon initiates adaptations to the host environment in response to LL-37Regulatory Targets of the Response Regulator RR_1586 from Clostridioides difficile Identified Using a Bacterial One-Hybrid Screen
P2860
Q26752597-BE89F5D2-064E-4BA9-AF7F-C59FB6A5B1D8Q27692563-E9C3185B-1695-43D7-BF0C-1F0A470D1399Q33641301-E0A60E18-C791-4569-8FA5-4D2BCE8C0ED9Q34298535-4574492F-CA08-4D1A-954E-B00C8352B980Q34306985-AFB4E99C-6425-4A3C-8348-C2032A3F7DAAQ34408053-27014D1C-D3D7-4191-990F-BB2AAE09D33FQ34549813-FBBC6795-54E7-4F07-B457-F9C2C7AA58F6Q35268648-90594F6C-BC84-454D-A18F-9B0E3D352BA0Q35746159-A2F22C6C-144B-48DE-BAC1-DC87220FEC25Q35940689-D78FCAA7-A138-49E7-BCE3-DA48CF333248Q36720179-B6C6A042-8A93-4C3B-A8A3-235BE344FDBDQ36984805-D19A2753-F2DB-4EE8-80EB-B070C6390B75Q37002320-EC02F5E2-CF12-40AD-91B1-17871D11843EQ37264144-34DB3CF3-24BF-4D8E-9642-3629EA42ADB6Q37424988-B4DBF535-6FF1-4B6A-9AA9-7EC01241D0D4Q37659614-76F37D25-A206-4833-8E0E-80EF6161AFB4Q38945513-2AB43A72-D98D-4684-B1DF-3A76BEF6BC1CQ38983244-987722F4-7156-4DF7-819F-522EFBE93BFAQ39433962-416E1C24-1E7D-4A65-9CBE-CB20738AA5D2Q40442110-FA0A0885-7973-41EC-B257-49D9E4BA72FDQ41608608-0DAA56F7-FCCC-42B2-BBF2-6C36676792F9Q47383314-0CF27E83-4B67-4087-B4EF-2C842E2C0AA2Q49177393-8FF8B968-3712-48E7-80C2-536AA91747DBQ52608578-E83D748F-6127-4E3A-8129-5593F653F2D8Q55307893-C30FC785-30E0-4D0C-9F12-06D3F486BD4EQ58734424-5949A9DD-A051-4904-A206-EB9AE6BF690FQ59130694-34D7EAC3-17CC-4564-8D7D-E071ACBECA24
P2860
The Clostridium difficile cpr locus is regulated by a noncontiguous two-component system in response to type A and B lantibiotics.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
The Clostridium difficile cpr ...... to type A and B lantibiotics.
@en
type
label
The Clostridium difficile cpr ...... to type A and B lantibiotics.
@en
prefLabel
The Clostridium difficile cpr ...... to type A and B lantibiotics.
@en
P2093
P2860
P356
P1476
The Clostridium difficile cpr ...... to type A and B lantibiotics.
@en
P2093
Adrianne N Edwards
Jose M Suárez
Shonna M McBride
P2860
P304
P356
10.1128/JB.00166-13
P407
P577
2013-03-29T00:00:00Z